Virax Biolabs
VRAX
4 hedge funds and large institutions have $183K invested in Virax Biolabs in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$241K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$81K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$59.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.96K |
Top Sellers
VRAX Hedge Fund Activity: Q3 2022 in Review
4 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2022, worth a combined $183K.
Buyers outnumbered sellers: 4 funds opened new VRAX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $241K.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q3 2022, up from 0 in Q2 2022.
- Funds reported $183K of Virax Biolabs stock for Q3 2022.
- 4 funds opened new Virax Biolabs positions in Q3 2022 and 0 closed out, a net change of +4 holders.
- The largest Virax Biolabs buyer in Q3 2022 was Schonfeld Strategic Advisors, an estimated $241K added.
Based on aggregated 13F filings for Q3 2022.